| pubmed-article:19101144 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19101144 | lifeskim:mentions | umls-concept:C0001814 | lld:lifeskim |
| pubmed-article:19101144 | lifeskim:mentions | umls-concept:C0063390 | lld:lifeskim |
| pubmed-article:19101144 | lifeskim:mentions | umls-concept:C1510827 | lld:lifeskim |
| pubmed-article:19101144 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:19101144 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19101144 | pubmed:dateCreated | 2009-1-27 | lld:pubmed |
| pubmed-article:19101144 | pubmed:abstractText | Compilation of agmatine structure and imidazoline ring leads to a new family of imidazoline/alpha(2)-adrenoceptor ligands, 4(5)-(2-aminoethyl)imidazoline derivatives. Constraining of the guanidine moiety into heterocyclic ring improved the affinities of the resultant fusion compounds in comparison to agmatine itself. In this work, the synthetic approach and results for I(1), I(2), and alpha(2)-adrenoceptors affinities are reported. | lld:pubmed |
| pubmed-article:19101144 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19101144 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19101144 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19101144 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19101144 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19101144 | pubmed:author | pubmed-author:HudsonAlan... | lld:pubmed |
| pubmed-article:19101144 | pubmed:author | pubmed-author:Andruszkiewic... | lld:pubmed |
| pubmed-article:19101144 | pubmed:author | pubmed-author:TrederAdam... | lld:pubmed |
| pubmed-article:19101144 | pubmed:author | pubmed-author:ZgodaW?odzimi... | lld:pubmed |
| pubmed-article:19101144 | pubmed:author | pubmed-author:FordCelesteC | lld:pubmed |
| pubmed-article:19101144 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19101144 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19101144 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19101144 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19101144 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19101144 | pubmed:pagination | 1009-11 | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:meshHeading | pubmed-meshheading:19101144... | lld:pubmed |
| pubmed-article:19101144 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19101144 | pubmed:articleTitle | New analogues of agmatine with higher affinity to imidazoline receptors. | lld:pubmed |
| pubmed-article:19101144 | pubmed:affiliation | Department of Pharmaceutical Technology and Biochemistry, The Faculty of Chemistry, Gda?sk University of Technology, Narutowicza St. 11/12, 80-952 Gda?sk, Poland. | lld:pubmed |
| pubmed-article:19101144 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19101144 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19101144 | lld:chembl |
